Benitec Biopharma Inc.

Benitec Biopharma Inc.

BNTC·NASDAQ

$10.70

+1.1%
HealthcareBiotechnology

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

At a Glance

Live Snapshot
Market Cap$280.84M
EPS-1.0500
P/E Ratio-10.19
Earnings Date09/28/2026

bntc

Shares Outstanding

Last Annual Value

36.21M

3-Year CAGR

166%

5-Year CAGR

173%

10-Year CAGR

82%

Benitec Biopharma Inc.

Benitec Biopharma Inc. Competitors Analysis of shares-outstanding

BNTC · NASDAQ
Companyshares-outstanding
CAGR 3Y
CAGR 5Y
CAGR 10Y
36.21M
196.7%104.6%78.3% 
IMAB logo
I-Mab
NASDAQ:IMAB
81.19M
-0.8%1.3%N/A
60.34M
15.1%15.6%N/A
46.98M
13.0%17.7%25.8%
57.33M
0.8%4.5%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
158.16M
15.2%31.7%N/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
9.40M
83.1%16.1%N/A
5.10M
2.1%8.3%N/A
230.12M
10.0%6.9%8.7%
2.41M
-55.7%-39.1%-20.2%
63.90M
2.0%1.8%8.1%
Benitec Biopharma Inc.

Benitec Biopharma Inc. Fair Value Envelope

BNTC · NASDAQ

Our analysis suggests that BNTC has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.7, this represents a potential HIDDEN relative to our calculated worth for Benitec Biopharma Inc..

Intrinsic Value
Current Price: $10.7